Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure.

Liu Y, Dillon AR, Tillson M, Makarewich C, Nguyen V, Dell'Italia L, Sabri AK, Rizzo V, Tsai EJ.

J Mol Cell Cardiol. 2013 Jul;60:72-83. doi: 10.1016/j.yjmcc.2013.03.019. Epub 2013 Apr 6.

2.

Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation.

Tsai EJ, Liu Y, Koitabashi N, Bedja D, Danner T, Jasmin JF, Lisanti MP, Friebe A, Takimoto E, Kass DA.

Circ Res. 2012 Jan 20;110(2):295-303. doi: 10.1161/CIRCRESAHA.111.259242. Epub 2011 Nov 17.

3.

Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.

Trappanese DM, Liu Y, McCormick RC, Cannavo A, Nanayakkara G, Baskharoun MM, Jarrett H, Woitek FJ, Tillson DM, Dillon AR, Recchia FA, Balligand JL, Houser SR, Koch WJ, Dell'Italia LJ, Tsai EJ.

Basic Res Cardiol. 2015 Jan;110(1):456. doi: 10.1007/s00395-014-0456-3. Epub 2014 Dec 6.

4.

The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.

Irvine JC, Ganthavee V, Love JE, Alexander AE, Horowitz JD, Stasch JP, Kemp-Harper BK, Ritchie RH.

PLoS One. 2012;7(11):e44481. doi: 10.1371/journal.pone.0044481. Epub 2012 Nov 7.

5.

Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.

Tunctan B, Korkmaz B, Sari AN, Kacan M, Unsal D, Serin MS, Buharalioglu CK, Sahan-Firat S, Cuez T, Schunck WH, Manthati VL, Falck JR, Malik KU.

Nitric Oxide. 2013 Sep 1;33:18-41. doi: 10.1016/j.niox.2013.05.001. Epub 2013 May 14.

6.

Regulation of VASP phosphorylation in cardiac myocytes: differential regulation by cyclic nucleotides and modulation of protein expression in diabetic and hypertrophic heart.

Sartoretto JL, Jin BY, Bauer M, Gertler FB, Liao R, Michel T.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1697-710. doi: 10.1152/ajpheart.00595.2009. Epub 2009 Sep 4.

7.

Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation.

Lin EQ, Irvine JC, Cao AH, Alexander AE, Love JE, Patel R, McMullen JR, Kaye DM, Kemp-Harper BK, Ritchie RH.

PLoS One. 2012;7(4):e34892. doi: 10.1371/journal.pone.0034892. Epub 2012 Apr 10.

8.

Protein kinase G phosphorylates soluble guanylyl cyclase on serine 64 and inhibits its activity.

Zhou Z, Sayed N, Pyriochou A, Roussos C, Fulton D, Beuve A, Papapetropoulos A.

Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1803-10. doi: 10.1161/ATVBAHA.108.165043. Epub 2008 Jul 17.

9.

Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation.

Holt AW, Martin DN, Shaver PR, Adderley SP, Stone JD, Joshi CN, Francisco JT, Lust RM, Weidner DA, Shewchuk BM, Tulis DA.

Cell Signal. 2016 Sep;28(9):1364-79. doi: 10.1016/j.cellsig.2016.06.012. Epub 2016 Jun 11.

10.

NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.

Bice JS, Keim Y, Stasch JP, Baxter GF.

Cardiovasc Res. 2014 Feb 1;101(2):220-8. doi: 10.1093/cvr/cvt257. Epub 2013 Nov 20.

11.

Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.

El-Sehemy A, Chang AC, Azad AK, Gupta N, Xu Z, Steed H, Karsan A, Fu Y.

Cell Signal. 2013 Dec;25(12):2780-7. doi: 10.1016/j.cellsig.2013.09.008. Epub 2013 Sep 13.

PMID:
24041655
12.

Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.

Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J.

Basic Res Cardiol. 2014 Jul;109(4):421. doi: 10.1007/s00395-014-0421-1. Epub 2014 Jun 8.

PMID:
24907870
13.

Roles for redox mechanisms controlling protein kinase G in pulmonary and coronary artery responses to hypoxia.

Neo BH, Kandhi S, Wolin MS.

Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2295-304. doi: 10.1152/ajpheart.00624.2011. Epub 2011 Sep 16.

14.

Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.

Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, Karas M, Stasch JP, Schmidt HH, Müller-Esterl W.

Circ Res. 2009 Jul 2;105(1):33-41. doi: 10.1161/CIRCRESAHA.109.198234. Epub 2009 May 28.

15.

A VASP-Rac-soluble guanylyl cyclase pathway controls cGMP production in adipocytes.

Jennissen K, Siegel F, Liebig-Gonglach M, Hermann MR, Kipschull S, van Dooren S, Kunz WS, Fässler R, Pfeifer A.

Sci Signal. 2012 Aug 28;5(239):ra62. doi: 10.1126/scisignal.2002867.

16.

HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: potential therapeutic advantages of HNO over NO.

Irvine JC, Cao N, Gossain S, Alexander AE, Love JE, Qin C, Horowitz JD, Kemp-Harper BK, Ritchie RH.

Am J Physiol Heart Circ Physiol. 2013 Aug 1;305(3):H365-77. doi: 10.1152/ajpheart.00495.2012. Epub 2013 May 31.

17.

Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.

Mujoo K, Sharin VG, Martin E, Choi BK, Sloan C, Nikonoff LE, Kots AY, Murad F.

Nitric Oxide. 2010 Jan 1;22(1):43-50. doi: 10.1016/j.niox.2009.11.007. Epub 2009 Dec 3.

18.

Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.

Goulopoulou S, Hannan JL, Matsumoto T, Ogbi S, Ergul A, Webb RC.

Am J Physiol Heart Circ Physiol. 2015 Jul 15;309(2):H297-304. doi: 10.1152/ajpheart.00079.2015. Epub 2015 May 8.

19.

Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling.

Mollnau H, Wendt M, Szöcs K, Lassègue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Förstermann U, Meinertz T, Griendling K, Münzel T.

Circ Res. 2002 Mar 8;90(4):E58-65.

20.

Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.

Boerrigter G, Burnett JC Jr.

Cardiovasc Drug Rev. 2007 Spring;25(1):30-45. Review.

PMID:
17445086

Supplemental Content

Support Center